- Daiichi Sankyo is investing €1 billion to expand its Pfaffenhofen site.
- The expansion will be completed by 2030, creating at least 350 new jobs.
- The site will develop therapies for breast, lung, and stomach cancer using ADC technology.
- A new ADC building is scheduled for completion by the end of 2026.
Investment and Expansion
Daiichi Sankyo is investing around €1 billion to expand its production and development site in Pfaffenhofen an der Ilm, north of Munich, into an international innovation center. The expansion, set to be completed by 2030, will create at least 350 new jobs, including positions for top international researchers, process engineers, and other specialists in sterile and biotechnology.
Focus on Cancer Therapies
The Pfaffenhofen site will not only continue to develop cardiovascular drugs but will also focus on therapies for breast, lung, and stomach cancer. New laboratories will be established, particularly for antibody drug conjugate (ADC) technology, which combines targeted therapy with the potency of chemotherapy.
Government Support
Federal Minister of Health Prof. Dr. Karl Lauterbach visited the plant, emphasizing the importance of this investment for Germany as a business location and for patients worldwide. He highlighted the government's efforts to promote pharmaceutical research and production by removing bureaucratic hurdles and creating fast approval channels.
Quality and Sustainability
For over 60 years, the Pfaffenhofen site has maintained high-quality standards, shipping medicines to more than 50 countries. The expansion includes a new building for ADC technology, scheduled for completion by the end of 2026. The site will also enhance its use of renewable energies, relying on wind, water, biomass, and solar energy, either generated on-site or in cooperation with local partners.
Collaboration and Future Viability
The expansion involves intensive collaboration with local, regional, and national partner companies. The focus on oncological therapies aims to meet the growing global demand for ADC cancer treatments and demonstrate the site's future viability and top quality.
